Cannabix Technologies Competitors

Asensus Surgical (NYSE:ASXC) and Cannabix Technologies (OTCMKTS:BLOZF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

0.1% of Cannabix Technologies shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Asensus Surgical and Cannabix Technologies' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and price targets for Asensus Surgical and Cannabix Technologies, as provided by MarketBeat.com.

Profitability

This table compares Asensus Surgical and Cannabix Technologies' net margins, return on equity and return on assets.

Summary

Cannabix Technologies beats Asensus Surgical on 1 of the 1 factors compared between the two stocks.

Cannabix Technologies (OTCMKTS:BLOZF) and Itamar Medical (NASDAQ:ITMR) are both small-cap business services companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Analyst Ratings

This is a breakdown of current ratings for Cannabix Technologies and Itamar Medical, as provided by MarketBeat.

Itamar Medical has a consensus price target of $31.00, suggesting a potential upside of 30.97%. Given Itamar Medical's higher possible upside, analysts plainly believe Itamar Medical is more favorable than Cannabix Technologies.

Insider and Institutional Ownership

0.1% of Cannabix Technologies shares are held by institutional investors. Comparatively, 29.4% of Itamar Medical shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Cannabix Technologies has a beta of 2.94, suggesting that its share price is 194% more volatile than the S&P 500. Comparatively, Itamar Medical has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Profitability

This table compares Cannabix Technologies and Itamar Medical's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Cannabix Technologies and Itamar Medical's top-line revenue, earnings per share (EPS) and valuation.

Cannabix Technologies has higher earnings, but lower revenue than Itamar Medical.

Summary

Itamar Medical beats Cannabix Technologies on 4 of the 5 factors compared between the two stocks.

Viemed Healthcare (NASDAQ:VMD) and Cannabix Technologies (OTCMKTS:BLOZF) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Viemed Healthcare and Cannabix Technologies, as provided by MarketBeat.com.

Viemed Healthcare currently has a consensus target price of $12.50, suggesting a potential upside of 28.87%. Given Viemed Healthcare's higher probable upside, research analysts plainly believe Viemed Healthcare is more favorable than Cannabix Technologies.

Insider and Institutional Ownership

0.1% of Cannabix Technologies shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Viemed Healthcare and Cannabix Technologies' gross revenue, earnings per share and valuation.

Profitability

This table compares Viemed Healthcare and Cannabix Technologies' net margins, return on equity and return on assets.

Summary

Viemed Healthcare beats Cannabix Technologies on 2 of the 3 factors compared between the two stocks.

Talis Biomedical (NASDAQ:TLIS) and Cannabix Technologies (OTCMKTS:BLOZF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Valuation & Earnings

This table compares Talis Biomedical and Cannabix Technologies' gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of current ratings and target prices for Talis Biomedical and Cannabix Technologies, as reported by MarketBeat.

Talis Biomedical currently has a consensus target price of $16.75, suggesting a potential upside of 20.07%. Given Talis Biomedical's higher probable upside, equities analysts clearly believe Talis Biomedical is more favorable than Cannabix Technologies.

Profitability

This table compares Talis Biomedical and Cannabix Technologies' net margins, return on equity and return on assets.

Insider & Institutional Ownership

0.1% of Cannabix Technologies shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Talis Biomedical beats Cannabix Technologies on 2 of the 3 factors compared between the two stocks.

Cannabix Technologies (OTCMKTS:BLOZF) and Xtant Medical (NYSEAMERICAN:XTNT) are both small-cap business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Insider and Institutional Ownership

0.1% of Cannabix Technologies shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Cannabix Technologies and Xtant Medical's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Cannabix Technologies and Xtant Medical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for Cannabix Technologies and Xtant Medical, as reported by MarketBeat.

Summary

Cannabix Technologies beats Xtant Medical on 1 of the 1 factors compared between the two stocks.

GBS (NYSE:GBS) and Cannabix Technologies (OTCMKTS:BLOZF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Insider and Institutional Ownership

0.1% of Cannabix Technologies shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares GBS and Cannabix Technologies' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for GBS and Cannabix Technologies, as provided by MarketBeat.

Earnings and Valuation

This table compares GBS and Cannabix Technologies' top-line revenue, earnings per share and valuation.

Summary

Cannabix Technologies beats GBS on 1 of the 1 factors compared between the two stocks.